top of page
Viscosity Reduction technology for Monoclonal Antibodies
Concentrations higher than 225mg/mL
Viscosity lower than 20cP
Upgrade your mAbs from IV to SubQ
The Qprotyn patented platform technology uses GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance.
Proof of Concept with your mAb in
8 Weeks !
bottom of page